PL1984344T3 - Multicykliczne pochodne aminokwasów oraz sposób ich stosowania - Google Patents

Multicykliczne pochodne aminokwasów oraz sposób ich stosowania

Info

Publication number
PL1984344T3
PL1984344T3 PL06849951T PL06849951T PL1984344T3 PL 1984344 T3 PL1984344 T3 PL 1984344T3 PL 06849951 T PL06849951 T PL 06849951T PL 06849951 T PL06849951 T PL 06849951T PL 1984344 T3 PL1984344 T3 PL 1984344T3
Authority
PL
Poland
Prior art keywords
methods
amino acid
acid derivatives
multicyclic
multicyclic amino
Prior art date
Application number
PL06849951T
Other languages
English (en)
Polish (pl)
Inventor
Arokiasamy Devasagayaraj
Haihong Jin
Qingyun Liu
Brent Marinelli
Lakshama Samala
Zhi-Cai Shi
Ashok Tunoori
Ying Wang
Wenxue Wu
Chengmin Zhang
Haiming Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PL1984344T3 publication Critical patent/PL1984344T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
PL06849951T 2005-12-29 2006-12-12 Multicykliczne pochodne aminokwasów oraz sposób ich stosowania PL1984344T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75495505P 2005-12-29 2005-12-29
EP06849951A EP1984344B1 (fr) 2005-12-29 2006-12-12 Derives d'acides amines multicycliques et procedes d'utilisation de ceux-ci
PCT/US2006/047579 WO2007089335A2 (fr) 2005-12-29 2006-12-12 Derives d'acides amines multicycliques et procedes d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
PL1984344T3 true PL1984344T3 (pl) 2013-03-29

Family

ID=38327831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06849951T PL1984344T3 (pl) 2005-12-29 2006-12-12 Multicykliczne pochodne aminokwasów oraz sposób ich stosowania

Country Status (21)

Country Link
US (3) US7723345B2 (fr)
EP (2) EP2386547B1 (fr)
JP (1) JP5483883B2 (fr)
KR (1) KR101360621B1 (fr)
CN (2) CN103265495B (fr)
AU (1) AU2006337137B2 (fr)
BR (1) BRPI0620756B1 (fr)
CA (1) CA2635531C (fr)
DK (1) DK1984344T3 (fr)
EA (1) EA019879B1 (fr)
EC (1) ECSP088590A (fr)
ES (2) ES2684821T3 (fr)
HK (1) HK1124841A1 (fr)
IL (1) IL191998A (fr)
NO (1) NO344848B1 (fr)
NZ (1) NZ568946A (fr)
PL (1) PL1984344T3 (fr)
PT (1) PT1984344E (fr)
UA (1) UA96936C2 (fr)
WO (1) WO2007089335A2 (fr)
ZA (1) ZA200805192B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1644375A2 (fr) 2003-07-14 2006-04-12 Arena Pharmaceuticals, Inc. Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
NZ590359A (en) 2005-01-25 2012-08-31 Synta Pharmaceuticals Corp Pyrazine compounds for inflammation and immune-related uses
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
ZA200805192B (en) * 2005-12-29 2009-11-25 Lexicon Pharmaceuticals Inc Multicyclic amino acid derivatives and methods of their use
EP2848610B1 (fr) * 2006-11-15 2017-10-11 YM BioSciences Australia Pty Ltd Inhibiteurs de l'activité de kinase
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
GB0705400D0 (en) * 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
BRPI0813212A2 (pt) * 2007-06-26 2014-12-23 Lexicon Pharmaceuticals Inc Métodos de tratamento de doenças e distúrbios mediados por serotonina
US8093291B2 (en) * 2007-06-26 2012-01-10 Lexicon Pharmaceuticals, Inc. Methods of using and compositions comprising tryptophan hydroxylase inhibitors
KR20100046189A (ko) * 2007-07-11 2010-05-06 렉시컨 파마슈티컬스 인코퍼레이티드 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
BRPI0813835A2 (pt) * 2007-07-26 2017-06-06 Lexicon Pharmaceuticals Inc métodos de afetar o trânsito gastrointestinal e esvaziamento gástrico, e compostos úteis a esse respeito
JP5553752B2 (ja) * 2007-08-24 2014-07-16 レクシコン ファーマシューティカルズ インコーポレイテッド ４−フェニル−６−（２，２，２−トリフルオロ−１−フェニルエトキシ）ピリミジン系化合物を調製する方法
US20100260772A1 (en) * 2007-09-28 2010-10-14 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
TWI439457B (zh) 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
TW200932729A (en) * 2007-10-08 2009-08-01 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use
KR20100115789A (ko) * 2008-02-04 2010-10-28 머큐리 테라퓨틱스, 인코포레이티드 Ａｍｐｋ 조절자
CN102083454A (zh) * 2008-03-31 2011-06-01 纽约市哥伦比亚大学托管会 诊断、预防和治疗骨量疾病的方法
WO2010011864A2 (fr) * 2008-07-23 2010-01-28 The Scripps Research Institute Mimétique alpha hélicoïdal à pyrazine fonctionnalisée
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
JP2012504642A (ja) * 2008-10-03 2012-02-23 レクシコン ファーマシューティカルズ インコーポレイテッド トリプトファンヒドロキシラーゼ阻害剤、及びこれらの使用方法
CA2741563A1 (fr) * 2008-10-24 2010-04-29 Lexicon Pharmaceuticals, Inc. Procede de preparation de phenylalanines substituees
WO2010062829A1 (fr) * 2008-11-28 2010-06-03 Lexicon Pharmaceuticals, Inc. Inhibiteurs de tryptophane hydroxylase pour traiter l’ostéoporose
WO2010065333A1 (fr) * 2008-12-01 2010-06-10 Lexicon Pharmaceuticals, Inc. Composés à base de 4-phényl-6-(2,2,2-trifluoro-1-phényléthoxy)pyrimidine pour le traitement de l’ostéoporose
US8815883B2 (en) * 2009-11-02 2014-08-26 The Trustees Of Columbia Unviersity In The City Of New York Compounds and methods for inhibiting serotonin synthesis
US20120316171A1 (en) * 2009-11-05 2012-12-13 Tamas Oravecz Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer
US20110124865A1 (en) 2009-11-19 2011-05-26 Shinya Iimura Process for the preparation of substituted phenylalanines
WO2011063181A1 (fr) 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Procédés et essais pour le traitement du syndrome du côlon irritable
US20120077831A1 (en) * 2009-11-23 2012-03-29 Philip Manton Brown Methods and assays for the treatment of irritable bowel syndrome
US20130137635A1 (en) 2010-02-10 2013-05-30 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
WO2011158108A2 (fr) 2010-06-16 2011-12-22 Purdue Pharma L.P. Indoles à substitution aryle et leur utilisation
EP3323818A1 (fr) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
TW201245183A (en) * 2010-11-05 2012-11-16 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
GB201203793D0 (en) * 2012-03-05 2012-04-18 Ge Healthcare Ltd Imaging neural activity
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
WO2014195847A2 (fr) 2013-06-03 2014-12-11 Actelion Pharmaceuticals Ltd Nouvelle utilisation du l-tryptophane marqué par un isotope stable
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
AR098436A1 (es) * 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
CA2927121A1 (fr) 2013-11-19 2015-05-28 Actelion Pharmaceuticals Ltd Composes imidazole tricycliques comme inhibiteurs de la tryptophane hydrolase
WO2015089137A1 (fr) * 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines comme inhibiteurs de la tryptophan hydroxylase
JPWO2015163435A1 (ja) 2014-04-24 2017-04-20 田辺三菱製薬株式会社 新規２−アミノ−ピリジン及び２−アミノ−ピリミジン誘導体及びその医薬用途
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HRP20211877T1 (hr) 2014-12-17 2022-03-04 Pimco 2664 Limited Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
WO2016109501A1 (fr) * 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Composés amides utilisés en tant qu'inhibiteurs de la tryptophane hydroxylase
EP3242666B1 (fr) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Composé pour le traitement des affections associés à s1p1-récepteur
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
JP2016204314A (ja) * 2015-04-23 2016-12-08 国立研究開発法人理化学研究所 化合物及び４−ボロノフェニルアラニン誘導体の製造方法
US20180155344A1 (en) * 2015-05-04 2018-06-07 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds
PT3310760T (pt) 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
CA3053418A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composes et methodes de traitement de l'angiocholite biliaire primitive
EP3674303B1 (fr) * 2017-08-24 2022-07-20 Gwangju Institute of Science and Technology Nouvel inhibiteur de la tryptophane hydroxylase et composition pharmaceutique le comprenant

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471146A (de) 1966-03-16 1969-04-15 Geigy Ag J R Verfahren zur Herstellung von neuen Morpholinderivaten
US4866181A (en) 1986-08-29 1989-09-12 Aldrich-Boranes, Inc. Process for producing optically active alcohols
US4916074A (en) 1986-10-30 1990-04-10 Chisso Corporation Process for producing optically active compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2121776T3 (es) 1991-03-21 1998-12-16 Solutia Europ Nv Sa Procedimiento catalitico mejorado para la alquilacion selectiva de hidrocarburos aromaticos.
DE4131924A1 (de) 1991-09-25 1993-07-08 Hoechst Ag Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ATE198748T1 (de) 1993-11-24 2001-02-15 Du Pont Pharm Co Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
GB9518553D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
DK0796855T3 (da) 1996-03-20 2002-05-27 Hoechst Ag Hæmmere af knogleresorption og vitronectin-receptorantagonister
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
WO1999009411A1 (fr) 1997-08-20 1999-02-25 Kyowa Medex Co., Ltd. NOUVEAU COMPOSE D'ACIDE 2-AMINO-3-[2-(α-MANNOPYRANOSYL)INDOL-3-YL]PROPIONIQUE, SON PROCEDE DE PREPARATION ET PROCEDE SERVANT A VERIFIER LE FONCTIONNEMENT D'UN CORPS VIVANT AU MOYEN DE CE NOUVEAU COMPOSE
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
CN1303286A (zh) * 1998-03-27 2001-07-11 法玛西雅厄普约翰美国公司 卡麦角林在治疗多动腿综合征中的应用
US6423727B1 (en) 1998-04-23 2002-07-23 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
JP2000204085A (ja) 1998-11-13 2000-07-25 Nippon Bayer Agrochem Co Ltd イソチアゾ―ルカルボン酸誘導体および病害防除剤
EE200100317A (et) 1998-12-16 2002-08-15 Bayer Aktiengesellschaft Uued bifenüül- ja bifenüülanaloogsed ühendid kui integriini antagonistid
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
ES2228458T3 (es) 1999-02-18 2005-04-16 F. Hoffmann-La Roche Ag Derivados de tioamida.
HUP0203338A2 (hu) 1999-04-13 2003-03-28 Abbott Gmbh & Co. Kg Integrin receptor ligandumok
US7045532B2 (en) * 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
AU5300000A (en) 1999-06-01 2000-12-18 Elan Pharma International Limited Small-scale mill and method thereof
EP1065208A1 (fr) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Dérivés substitués de la purine inhibiteurs de l'adhésion cellulaire
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
WO2001012183A1 (fr) 1999-08-16 2001-02-22 Merck & Co., Inc. Amides heterocycles comme inhibiteurs de l'adhesion cellulaire
WO2001021584A1 (fr) 1999-09-24 2001-03-29 Genentech, Inc. Derives de tyrosine
EP1239877B1 (fr) 1999-10-06 2008-01-09 Abbott GmbH & Co. KG Composition comprenant un inhibiteur du tnf-alpha et d'un antagoniste du recepteur alphavbeta3 d'integrine
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
KR20020048977A (ko) 1999-10-27 2002-06-24 딘 테일러 조직 인자 길항제 및 그의 사용 방법
WO2001036376A1 (fr) 1999-11-18 2001-05-25 Ajinomoto Co., Inc. Nouveaux dérivés de la phénylalanine
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
EP1244656A1 (fr) 1999-12-28 2002-10-02 Pfizer Products Inc. Inhibiteurs non peptidyle de liaison cellulaire dependant de vla-4 utiles pour le traitement de maladies inflammatoires, auto-immunes et respiratoires
EP1251730A4 (fr) 2000-01-26 2004-10-20 Univ Kansas State Preparation et utilisation de polymeres reticules avec des peptides contenant de la tyrosine
FR2804427B1 (fr) 2000-01-27 2002-09-06 Rhodia Chimie Sa Procede de preparation de cetones alpha-halogenees
WO2002000651A2 (fr) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
NZ523428A (en) 2000-06-28 2008-03-28 Prana Biotechnology Ltd Neurotoxic oligomers
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7015216B2 (en) 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
WO2002008206A1 (fr) 2000-07-21 2002-01-31 Elan Pharmaceuticals, Inc. Derives d'acide 3-amino-2-(4-aminocarbonyloxy)phenyl-proprionique, utilises comme inhibiteurs de l'integrine alpha-4
KR100675036B1 (ko) 2000-08-18 2007-01-29 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체 및 이를 포함하는 의약품
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
MY129000A (en) * 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
DE60124573T2 (de) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
ATE468325T1 (de) 2001-03-19 2010-06-15 Dainippon Sumitomo Pharma Co Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung
JP2004529918A (ja) 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物
CA2448347C (fr) 2001-05-29 2010-09-21 Lexicon Genetics Incorporated Nouvelles hydroxylases humaines et polynucleotides codant celles-ci
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
EP1392441B1 (fr) 2001-06-05 2008-07-23 Elan Pharma International Limited Systeme et procede de broyage de matieres
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
US20030171368A1 (en) 2002-02-06 2003-09-11 Werner Seitz Pyrimidinonesulfamoylureas`
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
EP1492780B1 (fr) 2002-04-03 2011-11-23 Novartis AG Derives 5-substitues 1,1-dioxo- 1,2,5]thiazolidine-3-one utilises en tant qu'inhibiteurs de ptpase 1b
AU2003235256A1 (en) 2002-04-19 2003-11-03 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
GB0213122D0 (en) 2002-06-07 2002-07-17 Glaxo Group Ltd Compounds
AU2003232941A1 (en) 2002-06-07 2003-12-22 Glaxo Group Limited N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
DE10234422A1 (de) 2002-07-29 2004-02-12 Bayer Ag Antibakterielle Ester-Makrozyklen
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
JPWO2004035522A1 (ja) 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
CA2498207C (fr) 2002-09-11 2012-03-13 Elan Pharma International Ltd. Compositions d'agents actifs nanoparticulaires stabilisees sous forme de gel
WO2004043349A2 (fr) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Derives d'isoxazoline comme inhibiteurs de metalloproteases matricielles et/ou d'enzyme de conversion de tnf-$g(a)
EP1575911B1 (fr) 2002-11-19 2010-01-13 Galderma Research & Development Nouveaux composes biaromatiques qui activent les recepteurs du type ppar-gamma et leur utilisation dans les compositions cosmetiques et pharmaceutiques
KR20050104339A (ko) * 2002-12-20 2005-11-02 파마시아 코포레이션 비환식 피라졸 화합물
ITMI20022738A1 (it) 2002-12-23 2004-06-24 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4.
ES2314271T3 (es) 2002-12-24 2009-03-16 Astrazeneca Ab Derivados de quinazolina terapeuticos.
WO2004080943A1 (fr) 2003-03-11 2004-09-23 Ono Pharmaceutical Co., Ltd. Procede permettant d'ajouter du charbon actif dans la purification d'eau et procede de purification d'eau
US20050187266A1 (en) 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US20050234066A1 (en) 2004-04-15 2005-10-20 Agouron Pharmaceuticals, Inc. Alpha substituted carboxylic acids
WO2004094426A1 (fr) 2003-04-21 2004-11-04 Ustav Organické Chemie A Biochemie Akademie Ved Ceské Republiky Acides (purin-6-yl) amines et procede de fabrication
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
MXPA05013645A (es) 2003-06-20 2006-02-24 Galderma Res & Dev Nuevos compuestos moduladores de los receptores de tipo ppar gama y su utilizacion en composiciones cosmeticas o farmaceuticas.
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
WO2005014532A1 (fr) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions et procedes associes
WO2005014533A2 (fr) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions et procedes d'utilisation
CA2540646A1 (fr) 2003-10-01 2005-04-14 Bayer Healthcare Ag Macrocycles d'amide antibacteriens
WO2005035551A2 (fr) 2003-10-08 2005-04-21 Incyte Corporation Inhibiteurs de proteines se liant a des molecules phosphorylees
JP2007509996A (ja) 2003-11-05 2007-04-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｐｐａｒ活性化剤としてのヘテロアリール誘導体
DE10358824A1 (de) 2003-12-16 2005-07-21 Bayer Healthcare Ag Antibakterielle Makrozyklen mit substituiertem Biphenyl
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
AU2005206885B2 (en) 2004-01-14 2012-02-02 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
JP2007126358A (ja) 2004-01-20 2007-05-24 Fujiyakuhin Co Ltd フェニルアラニン誘導体
ES2541779T3 (es) 2004-02-05 2015-07-24 The Ohio State University Research Foundation Péptidos VEGF quiméricos
AR047538A1 (es) 2004-02-10 2006-01-25 Janssen Pharmaceutica Nv Piridazinonas como antagonistas de las integrinas alfa4
US7585627B2 (en) 2004-05-21 2009-09-08 Duke University Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis
WO2006020358A2 (fr) 2004-07-27 2006-02-23 Smithkline Beecham Corporation Nouveaux composes de biphenyle et utilisation de ceux-ci
EP1786777A1 (fr) * 2004-08-26 2007-05-23 Pfizer, Inc. Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
ZA200805192B (en) * 2005-12-29 2009-11-25 Lexicon Pharmaceuticals Inc Multicyclic amino acid derivatives and methods of their use
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
US8093291B2 (en) * 2007-06-26 2012-01-10 Lexicon Pharmaceuticals, Inc. Methods of using and compositions comprising tryptophan hydroxylase inhibitors
KR20100046189A (ko) * 2007-07-11 2010-05-06 렉시컨 파마슈티컬스 인코퍼레이티드 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
TWI439457B (zh) * 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
TW200932729A (en) * 2007-10-08 2009-08-01 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use

Also Published As

Publication number Publication date
EP1984344A2 (fr) 2008-10-29
US7723345B2 (en) 2010-05-25
EP2386547B1 (fr) 2018-06-20
WO2007089335A3 (fr) 2007-10-11
US8063057B2 (en) 2011-11-22
CN103265495B (zh) 2016-11-16
WO2007089335A2 (fr) 2007-08-09
BRPI0620756B1 (pt) 2021-06-01
KR20080081159A (ko) 2008-09-08
ES2684821T3 (es) 2018-10-04
ZA200805192B (en) 2009-11-25
JP2009522265A (ja) 2009-06-11
US20100280054A1 (en) 2010-11-04
US20120157484A1 (en) 2012-06-21
NO344848B1 (no) 2020-05-25
CA2635531A1 (fr) 2007-08-09
AU2006337137A1 (en) 2007-08-09
HK1124841A1 (en) 2009-07-24
EA019879B1 (ru) 2014-07-30
CN101351451B (zh) 2013-02-20
US20070191370A1 (en) 2007-08-16
DK1984344T3 (da) 2013-01-14
NO20083324L (no) 2008-08-13
CN101351451A (zh) 2009-01-21
EA200870127A1 (ru) 2009-02-27
ECSP088590A (es) 2008-11-27
CN103265495A (zh) 2013-08-28
ES2395392T3 (es) 2013-02-12
BRPI0620756A2 (pt) 2011-11-22
NZ568946A (en) 2010-07-30
JP5483883B2 (ja) 2014-05-07
CA2635531C (fr) 2014-06-17
US8629156B2 (en) 2014-01-14
PT1984344E (pt) 2012-12-21
AU2006337137B2 (en) 2012-06-14
IL191998A0 (en) 2009-02-11
KR101360621B1 (ko) 2014-02-07
UA96936C2 (uk) 2011-12-26
EP2386547A1 (fr) 2011-11-16
IL191998A (en) 2015-01-29
EP1984344B1 (fr) 2012-09-26

Similar Documents

Publication Publication Date Title
IL191998A0 (en) Multicyclic amino acid derivatives and methods of their use
IL186490A0 (en) Multicyclic compounds and methods of their use
EP1843661A4 (fr) Compositions comportant des derives de o-acetylsalicyle de glucides amines et d'acides amines
EP1778210A4 (fr) Conjugues d'acides gras et amines et leur procedes d'utilisation
EP1909644A4 (fr) Appareil d'insertion et procédés d'utilisation
IL184735A0 (en) Pharmaceutical formulations and methods of use
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
PL2120921T3 (pl) Zastosowanie kwasu aminolewulinowego i jego pochodnych
EP1913112A4 (fr) Agent de soutenement et procedes d'utilisation
IL190953A0 (en) Cyclopropylacetic acid derivatives and use thereof
IL187360A0 (en) Tigecycline and methods of preparation
IL190955A0 (en) Dicarboxylic acid derivatives and their use
ZA200804688B (en) Purine derivatives and methods of use thereof
HK1213814A1 (zh) 雙氯芬酸製劑和使用方法
ZA200710173B (en) Tygecycline and methods of preparing 9-nitrominocycline
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1858535A4 (fr) Compositions a base d'actinidia et modes d'utilisation
EP1946007A4 (fr) Derives de l'androsterone et leur procede d'utilisation
EP1906953A4 (fr) Formes de sels acides et de sels basiques de gaboxadol
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
IL190583A0 (en) Pth formulations and methods of use
EP1845984A4 (fr) Derives de methylphenidate et leurs utilisations
EP1906950A4 (fr) Formulations d'ansamycine et leurs procedes d'utilisation
IL186277A0 (en) Dnt-maleate and methods of preparation thereof